Galera Therapeutics Inc

+0.02 (+1.42%)
Regulatory, Earnings Announcements

Galera Announces Results From Phase 1 Stage Of Greco-1 Trial Of Rucosopasem With SBRT For NSCLC

Published: 06/29/2022 11:36 GMT
Galera Therapeutics Inc (GRTX) - Galera Announces Results From Phase 1 Stage of Greco-1 Trial of Rucosopasem With Sbrt for Nsclc.
Galera Therapeutics Inc - Rucosopasem Was Safe and Well Tolerated.
Galera Therapeutics Inc - Early Indications of Anti-cancer Activity and Pulmonary Function Preservation.
Galera Therapeutics Inc - Enrollment Ongoing in Randomized, Double-blinded, Placebo-controlled Phase 2 Stage of This Trial.
Galera Therapeutics Inc - Completion of Enrollment for Phase 2 Stage of Trial Anticipated in Second Half of 2023.
Galera Therapeutics Inc - In-field Partial Responses Or Stable Disease Were Seen in Six of Seven Patients at Six Months Follow-up.
Galera Therapeutics Inc - All Seven Patients Are Alive Through a Minimum of Nine Months of Follow-up.
Galera Therapeutics Inc - Early Evidence of Protection of Pulmonary Function Was Observed Compared to Literature.
Galera Therapeutics Inc - No Grade 2-4 (rtog Scale) Declines in Dlco1 Were Seen in Any of Seven Patients Receiving Rucosopasem.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.49

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.41

More details on our Analysts Page.